Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alveofact and Budesonide in Preterm Neonatal RDS
NCT06367881Phase 1Recruiting
- Sponsor
- Ain Shams University
- Start
- Aug 2022
- Primary completion
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of calfactant and budesonide in respiratory distress syndrome (RDS) (4 arms), sponsored by Ain Shams University. Primary endpoint: Neutrophil Extracellular Trap formation at 48 hours. Started Aug 2022; status: recruiting.
02
Drugs
calfactantbudesonide
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on NCT06367881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06367881.